Literature DB >> 27662014

Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura.

Wenjing Cao1, Huy P Pham1, Lance A Williams1, Jenny McDaniel1, Rance C Siniard1, Robin G Lorenz1, Marisa B Marques1, X Long Zheng2.   

Abstract

Acquired thrombotic thrombocytopenic purpura is primarily caused by the deficiency of plasma ADAMTS13 activity resulting from autoantibodies against ADAMTS13. However, ADAMTS13 deficiency alone is often not sufficient to cause acute thrombotic thrombocytopenic purpura. Infections or systemic inflammation may precede acute bursts of the disease, but the underlying mechanisms are not fully understood. Herein, 52 patients with acquired autoimmune thrombotic thrombocytopenic purpura and 30 blood donor controls were recruited for the study. The plasma levels of human neutrophil peptides 1-3 and complement activation fragments (i.e. Bb, iC3b, C4d, and sC5b-9) were determined by enzyme-linked immunosorbent assays. Univariate analyses were performed to determine the correlation between each biomarker and clinical outcomes. We found that the plasma levels of human neutrophil peptides 1-3 and Bb in patients with acute thrombotic thrombocytopenic purpura were significantly higher than those in the control (P<0.0001). The plasma levels of HNP1-3 correlated with the levels of plasma complement fragment Bb (rho=0.48, P=0.0004) and serum lactate dehydrogenase (rho=0.28, P=0.04); in addition, the plasma levels of Bb correlated with iC3b (rho=0.55, P<0.0001), sC5b-9 (rho=0.63, P<0.0001), serum creatinine (rho=0.42, p=0.0011), and lactate dehydrogenase (rho=0.40, P=0.0034), respectively. Moreover, the plasma levels of iC3b and sC5b-9 were correlated (rho=0.72, P<0.0001), despite no statistically significant difference of the two markers between thrombotic thrombocytopenic purpura patients and the control. We conclude that innate immunity, i.e. neutrophil and complement activation via the alternative pathway, may play a role in the pathogenesis of acute autoimmune thrombotic thrombocytopenic purpura, and a therapy targeted at these pathways may be considered in a subset of these patients. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27662014      PMCID: PMC5394873          DOI: 10.3324/haematol.2016.149021

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  46 in total

1.  Neutrophil alpha-defensin human neutrophil peptide modulates cytokine production in human monocytes and adhesion molecule expression in endothelial cells.

Authors:  Y V Chaly; E M Paleolog; T S Kolesnikova; I I Tikhonov; E V Petratchenko; N N Voitenok
Journal:  Eur Cytokine Netw       Date:  2000-06       Impact factor: 2.737

2.  Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura.

Authors:  J A Cohen; M E Brecher; N Bandarenko
Journal:  J Clin Apher       Date:  1998       Impact factor: 2.821

3.  Acute ST-segment elevation myocardial infarction is associated with decreased human antimicrobial peptide LL-37 and increased human neutrophil peptide-1 to 3 in plasma.

Authors:  Hanjun Zhao; Hongbing Yan; Shizuya Yamashita; Wenzheng Li; Chen Liu; Yi Chen; Peng Zhou; Yunpeng Chi; Shaoping Wang; Bo Zhao; Li Song
Journal:  J Atheroscler Thromb       Date:  2011-12-21       Impact factor: 4.928

4.  Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.

Authors:  Cassandra C Deford; Jessica A Reese; Lauren H Schwartz; Jedidiah J Perdue; Johanna A Kremer Hovinga; Bernhard Lämmle; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

5.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

Authors:  W R Bell; H G Braine; P M Ness; T S Kickler
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

Review 6.  Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan.

Authors:  Y Fujimura; M Matsumoto; A Isonishi; H Yagi; K Kokame; K Soejima; M Murata; T Miyata
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

7.  High-resolution epitope mapping by HX MS reveals the pathogenic mechanism and a possible therapy for autoimmune TTP syndrome.

Authors:  Veronica C Casina; Wenbing Hu; Jian-Hua Mao; Rui-Nan Lu; Hayley A Hanby; Brandy Pickens; Zhong-Yuan Kan; Woon K Lim; Leland Mayne; Eric M Ostertag; Stephen Kacir; Don L Siegel; S Walter Englander; X Long Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-22       Impact factor: 11.205

8.  Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura: a retrospective multicenter study.

Authors:  Serdal Korkmaz; Muzaffer Keklik; Serdar Sivgin; Rahsan Yildirim; Anil Tombak; Mehmet Emin Kaya; Didar Yanardag Acik; Ramazan Esen; Sibel Kabukcu Hacioglu; Mehmet Sencan; Ilhami Kiki; Eyup Naci Tiftik; Irfan Kuku; Vahap Okan; Mehmet Yilmaz; Cengiz Demir; Ismail Sari; Fevzi Altuntas; Ali Unal; Osman Ilhan
Journal:  Transfus Apher Sci       Date:  2013-04-18       Impact factor: 1.764

Review 9.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

10.  Neutrophil antimicrobial peptide alpha-defensin causes endothelial dysfunction in porcine coronary arteries.

Authors:  Panagiotis Kougias; Hong Chai; Peter H Lin; Qizhi Yao; Alan B Lumsden; Changyi Chen
Journal:  J Vasc Surg       Date:  2006-02       Impact factor: 4.268

View more
  10 in total

1.  Human neutrophil peptide-1 inhibits thrombus formation under arterial flow via its terminal free cysteine thiols.

Authors:  Jenny K McDaniel; Mohammad S Abdelgawwad; Audra Hargett; Matthew B Renfrow; Khalil Bdeir; Wenjing Cao; Douglas B Cines; X Long Zheng
Journal:  J Thromb Haemost       Date:  2019-03-13       Impact factor: 5.824

2.  Relative Deficiency of Plasma A Disintegrin and Metalloprotease with Thrombospondin Type 1 Repeats 13 Activity and Elevation of Human Neutrophil Peptides in Patients with Traumatic Brain Injury.

Authors:  Monisha A Kumar; Wenjing Cao; Huy P Pham; Dheeraj Raju; Kelsey Nawalinski; Eileen Maloney-Wilensky; James Schuster; X Long Zheng
Journal:  J Neurotrauma       Date:  2018-08-14       Impact factor: 5.269

Review 3.  Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.

Authors:  M Saha; J K McDaniel; X L Zheng
Journal:  J Thromb Haemost       Date:  2017-07-27       Impact factor: 5.824

4.  Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy.

Authors:  Liang Zheng; Di Zhang; Wenjing Cao; Wen-Chao Song; X Long Zheng
Journal:  Blood       Date:  2019-08-13       Impact factor: 22.113

5.  Low Plasma ADAMTS13 Activity Is Associated with Coagulopathy, Endothelial Cell Damage and Mortality after Severe Paediatric Trauma.

Authors:  Robert T Russell; Jenny K McDaniel; Wenjing Cao; Michelle Shroyer; Brant M Wagener; X Long Zheng; Jean-François Pittet
Journal:  Thromb Haemost       Date:  2018-04-04       Impact factor: 5.249

6.  Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura.

Authors:  Jingrui Sui; Ruinan Lu; Konstantine Halkidis; Nicole K Kocher; Wenjing Cao; Marisa B Marques; X Long Zheng
Journal:  J Thromb Haemost       Date:  2021-01-03       Impact factor: 5.824

7.  Clinical factors and biomarkers predict outcome in patients with immune-mediated thrombotic thrombocytopenic purpura.

Authors:  Elizabeth M Staley; Wenjing Cao; Huy P Pham; Chong H Kim; Nicole K Kocher; Lucy Zheng; Radhika Gangaraju; Robin G Lorenz; Lance A Williams; Marisa B Marques; X Long Zheng
Journal:  Haematologica       Date:  2018-08-31       Impact factor: 9.941

Review 8.  Insights Into Immunothrombosis: The Interplay Among Neutrophil Extracellular Trap, von Willebrand Factor, and ADAMTS13.

Authors:  Junxian Yang; Zhiwei Wu; Quan Long; Jiaqi Huang; Tiantian Hong; Wang Liu; Jiangguo Lin
Journal:  Front Immunol       Date:  2020-12-02       Impact factor: 7.561

9.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08

10.  Histone-induced thrombotic thrombocytopenic purpura in adamts13 -/- zebrafish depends on von Willebrand factor.

Authors:  Liang Zheng; Mohammad S Abdelgawwad; Di Zhang; Leimeng Xu; Shi Wei; Wenjing Cao; X Long Zheng
Journal:  Haematologica       Date:  2019-11-21       Impact factor: 9.941

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.